Categories

Cables & Cable Assemblies

Consumer Products

Electronic Components & Electrochemical Materials

Fabrics

Fibers

Filtration

Medical Products

Ozonation Modules

Pharmaceutical & Biopharmaceutical

Sealants

Venting

News

Shared Purpose: Gore’s 2022 Enterprise New Sustainability Update

Posted July 11, 2023

In this 2022 Enterprise Sustainability Update our sustainability efforts — across purposeful innovation, environmental stewardship, and enhancing our social impact — stay true to our core values and uphold our brand promise: Together, improving life.

Press Release

Gore Acquires InnAVasc Medical, Inc.

Posted August 12, 2022

W. L. Gore & Associates, Inc. (Gore) announced the acquisition of InnAVasc Medical, Inc., a privately held medical technology company focused on advancing care for patients with end stage renal disease who utilize graft circuits for dialysis treatment.

Press Release

Physicians in the U.S. Begin Commercial Use of the GORE® Excluder® Conformable AAA Endoprosthesis With Active Control System

Posted March 29, 2021

Today, W. L. Gore & Associates, Inc. (Gore) announces the first use of the FDA approved GORE® EXCLUDER® Conformable AAA Endoprothesis with ACTIVE CONTROL System in cases outside of clinical trials. Cases were successfully performed by Robert Rhee, M.D. with Mahmoud Almadani, M.D., in Brooklyn, New York and by Gustavo Oderich, M.D. with Naveed Saqib, M.D., in Houston, Texas.

Press Release

W. L. Gore & Associates Announces Encouraging Six-month Results with Its Novel Biosynthetic Tissue Valve

Posted November 18, 2020

W. L. Gore & Associates, Inc. (Gore), a global leader in providing solutions for cardiovascular disease, today announced encouraging clinical results from its early feasibility study evaluating the safety and performance of its pulmonary valved conduit, an investigational device.

Press Release

Gore Receives CE Mark for the GORE® CARDIOFORM ASD Occluder for the Treatment of Atrial Septal Defects in Europe

Posted October 2, 2019

W. L. Gore & Associates has introduced the newest member of its family of occluders, the GORE® CARDIOFORM ASD Occluder, which has received CE Mark. The device offers physicians a clinically proven design in a device that, in a recent study, met its primary endpoint for the percutaneous, transcatheter closure of ostium secundum atrial defects (ASDs).

Press Release

GORE® ENFORM Biomaterial Earns Innovative Technology Designation from Vizient, Inc.

Posted July 17, 2019

W. L. Gore & Associates announced that GORE® ENFORM Biomaterial for use in abdominal wall reconstruction procedures recently received the Innovative Technology designation from Vizient, Inc., the largest member-driven health care performance improvement company in the U.S.

Press Release

First U.S. Patient Receives GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL

Posted July 10, 2019

Gore announces the first U.S. implant of the GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System. This first case follows the recent FDA approval for this new device.

Press Release

GORE® CARDIOFORM ASD Occluder Receives FDA Approval for the Treatment of Atrial Septal Defects

Posted June 4, 2019

W. L. Gore & Associates announced the U.S. Food and Drug Administration’s (FDA’s) premarket approval (PMA) of the GORE® CARDIOFORM ASD Occluder for the percutaneous closure of ostium secundum atrial septal defects (ASDs).

Press Release

Gore Receives FDA Approval for the GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL

Posted May 15, 2019

W. L. Gore & Associates, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted regulatory approval for commercial distribution for the GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System, a unique Thoracic Endovascular Aortic Repair (TEVAR) solution combining new levels of control with the proven legacy and trusted performance of the Conformable GORE® TAG® Device.

Press Release

Gore to Showcase GORE® ENFORM Biomaterial - A New Synthetic and Absorbable Biomaterial for Abdominal Wall Reconstruction - at the American Hernia Society (AHS) Annual Meeting

Posted March 5, 2019

W. L. Gore & Associates, Inc. (Gore) will showcase its new GORE® ENFORM Biomaterial, a fully synthetic and absorbable biomaterial designed for optimal handling and tissue response, at the AHS annual meeting in Las Vegas on March 11-14, 2019.

Press Release

GORE® TIGRIS® Vascular Stent Demonstrates High Patency Rates at 12 Months in Treating SFA and PPA Occlusive Lesions in Challenging Patients

Posted January 24, 2019

The GORE® TIGRIS® Vascular Stent demonstrated that it is a safe and effective device that can be incorporated into a modern “leave-nothing-behind” treatment algorithm that reserves stent usage for more challenging patients.

Press Release

Gore Celebrates 15th Anniversary of Market-Leading GORE® SEAMGUARD® Bioabsorbable Staple Line Reinforcement

Posted November 12, 2018

W. L. Gore & Associates, Inc. (Gore) is celebrating the 15th Anniversary of its GORE® SEAMGUARD® Bioabsorbable Staple Line Reinforcement, a synthetic buttressing material engineered to reduce leaks and bleeding in a variety of minimally-invasive weight loss procedures, including sleeve gastrectomy and gastric bypass.

Press Release

Gore to Highlight Real-World Aortic Data at 45th Annual VEITHsymposium®

Posted November 8, 2018

W. L. Gore & Associates, Inc. (Gore) will highlight data gleaned from its Global Registry for Endovascular Aortic Treatment (GREAT) Study at the 45th Annual Symposium on Vascular and Endovascular Issues, VEITHsymposium® in New York.

Load more news